Date	Event	Presentation	Speakers
December 4, 2012	4th World Epigenetics Summit	Epigenetics - Impact for Translational and Drug Safety Sciences	Remi Terranova
November 3, 2010	DIAâ€™s 8th Annual Canadian Meeting: â€œKeeping Canada on the Map: Fostering Innovation and Access to Drugs in Canadaâ€�	TRACK 1 – Clinical Development - Innovations in Clinical Development	Diane Colizza
		TRACKS 2 and 3 – Reimbursement/Regulatory - Common Drug Review Pre-NOC	Alain Boisvert
		Adaptive Clinical Trial Designs: Where Is Industry with Respect to Adaptive Design?	Jeffrey Maca
August 25, 2010	Co-Development of Drugs and Diagnostics	Lumiracoxib - Seeking a New Path Forward Through Use of a Companion Diagnostic	Kevin Carl
May 19, 2010	Towards Personalized Cancer Medicine	The Discovery and Application of Cancer Therapeutics in the Genomic Era	William R Sellers
		PANEL DISCUSSION	William R Sellers
November 2, 2009	Track 4: Fourth Annual GPCR-based drug discovery	Targeting GPCR Activity: Conventional and Novel Label-free cAMP Assays Sandra Siehler, Ph.D., Research Investigator II, Novartis Institute for BioMedical Research	Sandra Siehler
November 2, 2009	Track 3: Fourth Annual Ion Channels as Therapeutic Targets	Evaluation of Available Technologies for Ligand-gated Ion Channel Safety Profiling and Screening	Gul Erdemli
September 24, 2009	Track 2: Implementing Personalized Medicine : Inaugural Targeted Therapy	Biomarkers - Driven Drug and Diagnostic Co-Development in Oncology: Current Trends and Future Approaches	Miro Venturi
August 24, 2009	Specialized Protein Expression Systems	Baculovirus Generated Proteins for Structure-Based Drug Design: Lessons Learned	James Groarke
		Exploring the Myth of Glycosylation for Crystallization	Paul Ramage
August 17, 2009	Fourth Annual Novel Vaccines: Design & Development	Structure-Based Rational Design of HIV Env Immunogens for Vaccine Development	Indresh K. Srivastava
August 5, 2009	Drug Safety Strategies to De-Risk Compounds	in silico Methods in Drug Safety	Josef Scheiber
July 1, 2009	Advances in Oral Dose Manufacturing	Assessing the Effects of API Particle Size	Jeewan Thakur
		Applying Solid Dispersion and Nanoparticulate Manufacturing Technologies for Enhanced Drug Delivery	Carsten Timpe
June 10, 2009	Second Annual Hepatotoxicity and Drug Safety	KEYNOTE PANEL DISCUSSION	Laszlo Urban
June 9, 2009	Inaugural The Expanding Impact of New Animal Models in Drug Safety	Early Prediction of Clinical Adverse Drug Reactions: in vitro Safety Pharmacology	Laszlo Urban
June 8, 2009	RNAi for Functional Screens	Development of a Flexible RNAi Screening Platform for Drug Discovery	Anthony Orth
		Chairperson’s Remarks	Anthony Orth
June 4, 2009	Structure-Based Drug Design	Main Conference	Indresh K. Srivastava
June 1, 2009	Combination Products	Best Practices for Performing Risk Assessment: How are small and large companies doing this?	Gangadhar Sunkara
		Chairperson’s Opening Remarks	Gangadhar Sunkara
May 19, 2009	Amorphous Materials	Evaluation of the Performance of Amorphous Dispersion	Dieter Becker,
May 12, 2009	BioAvailability and BioEquivalence	Statistical Issues in Biosimilarity	Sandro Gsteiger
April 22, 2009	PI 3-Kinase Signaling in Disease (Z3)	Keynote Address	William R Sellers
April 7, 2009	Kinase Inhibitor Chemistry - Charting the Chemical Space	Iterative Kinase Medium-Throughput Screening with 2D profile-QSAR and 3D AutoShim Models	Eric Martin
April 6, 2009	Fourth Annual FRAGMENT-BASED DRUG DISCOVERY	Virtual Fragment Linking: An Approach to Identify Potent Binders from Low Affi nity Fragment Hits	Meir Glick
March 17, 2009	Bio Medical Asia 2009	Concept for integration of QbD for enhanced efficiency in biologics process development	Christian H. Leist
March 16, 2009	High Throughput Screening for Biological Systems	IN VITRO SCREENING FOR METABOLIC STABILITY TO PROVIDE CHEMISTRY ALTERNATIVES	Alfred Zimmerlin
		MODULATION OF mRNA STABILITY AS A DRUG DISCOVERY PLATFORM	Christian Parker
February 24, 2009	Pharmaceutical Analysis Course	Overview of the regulatory directives governing the commercial area	Andreas Trute
February 23, 2009	Advances and Progress in Drug Design VIII	KEY ASPECTS FOR THE DESIGN OF A COMPREHENSIVE DRUG DISCOVERY SCREENING COLLECTION	Edgar Jacoby
February 17, 2009	Pharma/Biotech Patent Litigation	Chair’s Opening Remarks	Peter de Weerd
		Ensuring that Strategic Litigation Decisions are Aligned with International Business Goals	Peter de Weerd
February 9, 2009	Immunogenicity for Biologics 2009	Parallel analysis of exposure and immunogenicity by Biacore in pre-clinical studies	Annette Zaar
February 8, 2009	CHEMISTRY IN CANCER RESEARCH: A Vital Partnership in Cancer Drug Discovery and Development	Session 3: Chemistry in Support of Lead Discovery/Screening, Hit Validation, and Natural Products	Jeremy S. Caldwell
		Session 6: Chemistry in Support of Cancer Drug Discovery/Case Histories II	Jean Cuiné,
January 26, 2009		Use of Biomarkers and Translational Science to Accelerate and Improve Oncology Drug Development: Opportunities and Roadblocks	J Carl Barrett
January 26, 2009	Biomarker Assay Development	Use of Biomarkers and Translational Science to Accelerate and Improve Oncology Drug Development: Opportunities and Roadblocks	J Carl Barrett
		Opportunities and Challenges of Biomarker Assays in Drug Development	Francois Legay
		Target-Related Pharmacodynamic Analysis to Guide Successful Development of Biological Therapies: Novel Biomarker Concepts and Analytical Strategies	Miro Venturi
January 26, 2009	Translational Cancer Medicine	Use of Biomarkers and Translational Science to Accelerate and Improve Oncology Drug Development: Opportunities and Roadblocks	J Carl Barrett
		TRANSLATIONAL IMAGING : Translational Molecular Imaging: Oncology	Syed Mahmood
January 26, 2009	7th Annual Partnering with Central Labs	B2 : The Use of Imaging Biomarkers in Phase I/II trials	Haren Rupani
		Technical Hot Topics	Haren Rupani
		Track A : Improve Patient Care, Transparency and Process Efficiency in Global Studies	Scott Sawicki
		Track A : Central Lab Cost Drivers and Logistics Discussion Forum	Scott Sawicki
January 5, 2009	High Content Analysis	High-Content Screen to Look for Inhibitors of Virus Entry	Marjo Simonen
		Evaluation of Data Analysis Tools for the Multivariate Classification of Compound Responses Detected by High-Content Screening	Anne Kuemmel
December 9, 2008	3rd Annual Congress Strategies to enhance Solubility and Drug Absorption	Drug solubilisation strategies: Applying solid dispersion and nanoparticulate formulation approaches in drug development	Carsten Timpe,
		Lipid-based drug delivery systems to enhance solubility and absorption of poorly water-soluble drugs	Jean Cuiné,
		From animal-to-man: Pharmacokinetics and scalability to humans - a formulators’ perspective	Dieter Becker,
December 2, 2008	2nd Annual:Outsourcing Preclinical Development	Outsourcing DMPK studies	Miro Venturi,
December 2, 2008	2nd Annual: Pre-clinical and clinical safety testing for new drugs	Improving translation to clinical trials through the use of human hepatocytes in culture	Armin Wolf,
		What could be introduced into the pre-clinical toolkit to more accurately predict TdP risk. Is this necessary?	Bérengère Dumotier
December 2, 2008	4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development	1: The use of in vivo models in drug discovery imaging	Thomas Krucker,
		2 : Panel Debate: How translatable is preclinical and clinical imaging?	Raymond Josephsson,
		2 : The importance of translatability in imaging and how this can improve preclinical and clinical trials	Raymond Josephsson,
		2 : Exploratory imaging in oncology clinical trials - Where are we today?	Haren Rupani
December 2, 2008	2nd Annual Lead Discovery Summit 2008:-Compound Library Design, Synthesis & Acquisition	Type 2 and type 3 kinase targeting compound libraries	Doriano Fabbro,
		Decision criteria in cherry picking compounds from large collections for screening campaigns: What have been the most successful methods?	Ansgar Schuffenhauer,
December 2, 2008	The 8th World Drug Discovery & Development Summit 2008	PREDICTING DRUG PROMISCUITY	Jacques Hamon
November 26, 2008	4th Annual Audits and Inspections for Clinical Trials and Pharmacovigilance	Maximising the value of CRO relationships in developing audits together	Elisabetta di Martino,
November 25, 2008	6th Annual Stability Testing for Pharmaceuticals	Management of OOS and OOT results	Joseph Kottathu
November 17, 2008	Mastering Process Chemistry	Large-Scale Synthesis of Discodermolide, a Marine Natural Product for the Treatment of Advanced Solid Tumors	Frederick Kinder
November 17, 2008	BIO-Europe 2008	What Buyers Want: Understanding What Big Pharma Expect to See in Out-Licensing Documents	Axel Maibuecher
November 12, 2008	Third Annual Post-Approval Drug Safety Strategies: Best Practices to Mitigate Risks throughout the Product's Life Cycle	Chairperson’s Remarks	John Ferguson
		Plotting a Strategy for the Best Benefit-Risk Ratio	John Ferguson
November 12, 2008	11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements	Successfully Negotiating Collaborative Research Agreements with Academic Institutions	Stephanie Oestreich
November 11, 2008	Stability Testing for Biologics	Characterisation of degradation products of antibodies using HPLC and mass spectrometry	Hui Zhao
November 4, 2008	Bioanalytical Autumn School	Comparability - choosing the correct analytical tools	Claudia Magagnoli
October 20, 2008	Protein Expression Europe	The Benefits of Fusion Tags for an Improved Protein Production with E. coli and BEVS	Lukas Leder
		Baculovirus and E.coli- Generated Proteins for Structure-Based Drug Design – Lessons Learned	James M Groarke
October 14, 2008	Crystal Form Selection and Crystallisation of API	Opening remarks from the Chairperson	Peter Karpinski
		Closing remarks from the Chairperson	Peter Karpinski
October 12, 2008	15th North American Regional Meeting - International Society for the Study of Xenobiotics	The TeGenero Story: What Happened at Northwick Park and Lessons Learned	Jenny Sims
September 29, 2008	Genomic Biomarkers	Biomarker Application in Oncology Clinical Development	Michael Shi
September 17, 2008	BACULOVIRUS TECHNOLOGY	Multi-Parallel Protein Production: Overcoming the Challenges to Accelerate Structural Based Drug Design	Ian Hunt
June 19, 2008	Virtual Discovery Europe	Integration of Image-Based Cytological Phenotypes with Computational Ligand-Target Prediction to Identify Mechanisms of Action	Andreas Bender
June 18, 2008	Accelerating Anticancer Agent Development and Validation Workshop	Harmonization of International Standards for Oncology Products	Daniel Lapadula
		Panel Discussion	Daniel Lapadula
May 18, 2008	G Protein-Coupled Receptors: New Insights in Functional Regulation and Clinical Application (E2)	Deorphanized GPCRs	Deborah Nguyen
May 4, 2008	Impact China IV: Pharmaceutical R&D Global Summit	Keynote Address: Chinese SFDA and Global Drug Development - Quality, Science and Speed	Paul Dai
March 31, 2008	Pharmaceutical Sales & Marketing Executive Congress: Generating BIG Returns in a Changing Compliance Environment	The ‘State of the Industry’ – Challenges & Opportunities in 2008 and Beyond	Lori Ryan
March 31, 2008	China 2008 Pharmaceutical R&D Summit	Leveraging Traditional Chinese Medical Knowledge for Modern Medicine: Collaborating with the Shanghai Institute of Materia Medica	Paul Herrling
		Global Pharma Exchange Roundtable	En Li
		Track II Clinical Research Development in China – Experiences, Improvements and Changes Chairperson’s Opening Remarks	Paul Dai
March 25, 2008	Preclinical Development	Mechanistic Cardiac Modeling: Concepts and Utility in Drug Development	Anna Georgieva
		Predictive Value of in Vitro Safety Studies	Willi Suter
		Imaging in Phase II/III Clinical Development	Haren Rupani
March 25, 2008	TRANSLATIONAL MEDICINE	Imaging in Phase II/III Clinical Development	Haren Rupani
March 25, 2008	TRENDS IN DRUG SAFETY	Mechanistic Cardiac Modeling: Concepts and Utility in Drug Development	Anna Georgieva
		Predictive Value of in Vitro Safety Studies	Willi Suter
March 19, 2008	The Healthcare Dealmaking Symposium	Licensing Deals	Jeremy M. Levin
February 19, 2008	Screening Europe	Track A Modern Approaches for an Old Problem: High-Throughput Screening and Compound Profiling of Proteases	Lorenz Mayr
		Track B Emerging GPCR Assay Technologies for Drug Discovery	Sandra Siehler
February 18, 2008	Fragment-based Lead Discovery Conference	Successes and Surprises with Fragments	Wolfgang Jahnke
		Morning Session: Methods & Emerging Technologies, Part I	Wolfgang Jahnke
		In vivo Incorporation of NMR-active Unnatural Amino Acids	Bernhard Geierstanger
December 4, 2007	7th World Drug Discovery & Development Summit 2007	Conference room 2 OPTIMISING TECHNOLOGIES TO INCREASE SPEED TO CLINIC AND SPEED TO MARKET	Hans-Peter Knopf
December 1, 2007	47TH American Socieity of Cell Biology	Solving Cell Culture Problems:	Lori Ryan
November 15, 2007	Second Annual Drug Development India : Planning and Managing Drug Discovery & Development Activities Nov(15-16)	CONTRIBUTION OF ACADEMIC INSTITUTES (13:30-15:00)	Gangadhar Sunkara
		CONTRIBUTION OF ACADEMIC INSTITUTES: Pharmaceutical Research and Development Environment in India: The Contribution of Aca-demic Institutes (13:30-14:00)	Gangadhar Sunkara
		PRECLINICAL DEVELOPMENT AND CHALLENGES (15:30-18:45)	Gangadhar Sunkara
		PRECLINICAL DEVELOPMENT AND CHALLENGES: INTERACTIVE PANEL :Partnership and Outsourcing Deals in India – Successes and Failures (17:00-17:45)	Gangadhar Sunkara
November 5, 2007	Bio-Pharma Alliance Summit Nov (05-06)	The Novartis / Human Genome Sciences Albuferon Alliance – Key Success Factors in Driving Successful Biotech/Big Pharma Alliances (14:35-15:15)	Mark Coflin
October 17, 2007	Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18)	CRAC – AN EMERGING TARGET (08:35-09:40)	Martin Gosling
		CRAC – AN EMERGING TARGET: Chairperson’s Remarks (08:35-08:40)	Martin Gosling
		TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY: Screening Ion Channel Targets with Therapeutic Potential in Respiratory Disease: Application of Automated Electrophysiology (09:40-12:25)	Martin Gosling
		TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY (09:40-12:25)	Martin Gosling
October 16, 2007	Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17	SESSION I: LAYING THE GROUND WORK FOR EARLY DECISION MAKING (13:45 - 19:00)	Jose Pinheiro
		SESSION I: Evaluating Adaptive Dose-Ranging Studies: Conclusions and Recommendations from the PhRMA Working Group (16:00 - 16:30)	Jose Pinheiro
October 15, 2007	2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16)	Keynote Presentation (08:45-09:30)	J Carl Barrett
October 11, 2007	Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12)	SCREENING AGAINST MULTIPLE TARGETS (Shared Session with Drug Repositioning Summit) (12:30-17:15)	Jeremy S. Caldwell, Laszlo Urban
		SCREENING AGAINST MULTIPLE TARGETS: Integrative In Vitro Safety Pharmacology Profiling to Predict Clinical Adverse Effects (15:45-16:15)	Laszlo Urban
		SCREENING AGAINST MULTIPLE TARGETS: Automated Robotic Molecular Profiling in Cells for New Therapeutic Directions (14:15-14:45)	Jeremy S. Caldwell
		SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30)	Andreas Bender
		SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Compound Profiling by Predicting On-Target Activities, Compound Promiscuity and Adverse Drug Reactions (16:00-16:30)	Andreas Bender
October 10, 2007	Drug Repositioning Summit: Finding New routes to success (Oct 10-11)	SCREENING AGAINST MULTIPLE TARGETS: Automated Robotic Molecular Profiling in Cells for New Therapeutic Directions (14:15-14:45)	Jeremy S. Caldwell
		SCREENING AGAINST MULTIPLE TARGETS (Shared Session with Compound Profiling) (13:30-17:15)	Jeremy S. Caldwell, Laszlo Urban
		SCREENING AGAINST MULTIPLE TARGETS: Broad-Scale In Vitro Pharmacology Profiling to Predict Clinical Adverse Effects and for ADME Profiling (15:45-16:15)	Laszlo Urban
October 2, 2007	IVT 's Lab Week	Requirements Definition \| Session 8	Susan Cleary, Parsa Famili
		Writing Requirements Keeping Validation in Mind \| Session 8	Susan Cleary, Parsa Famili
		Finalizing the System \| Session 8	Susan Cleary, Parsa Famili
		Interactive Exercise \| Session 8	Susan Cleary, Parsa Famili
September 27, 2007	Protein Expression Europe (Sep 27-28)	Drug Discovery Applications (13:00-15:15)	Lorenz Mayr
		Drug Discovery Applications: Miniaturization and Automation of Protein Expression for High-Throughput Screening and Structural Biology (13:15-13:45)	Lorenz Mayr
September 19, 2007	Baculovirus Technology (Sep 19-20)	Protein Production (13:45-16:00)	Ian Hunt
		Protein Production: Baculovirus Mediated Protein Production - Overcoming the Challenges to Accelerate Drug Discovery (13:50-14:25)	Ian Hunt
		Protein Expression: A Fast and Multi-Parallel Approach for Small-Scale Expression Screening Using the BEVS System (16:30-17:00)	Aline Tirat-Boeuf
		Protein Expression (16:00-19:00)	Aline Tirat-Boeuf

BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.